The seven-row TL;DR
For each dimension where one drug clearly wins, we name the winner. Where the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| Trial weight loss | Zepbound (20.9%) > Wegovy (14.9%) | Zepbound |
| Mechanism | Dual GLP-1/GIP (Zepbound) vs GLP-1 only (Wegovy) | Zepbound |
| Cash price at maintenance dose | LillyDirect $549 vs NovoCare $499 | Wegovy |
| DTC starting dose | NovoCare $199 vs LillyDirect $349 | Wegovy |
| Insurance coverage in 2026 | Both covered by most commercial; Wegovy has slight edge on Medicare Part D | Wegovy |
| Real-world track record | Wegovy launched 2021; Zepbound launched late 2023 | Wegovy |
| OSA indication | Zepbound is FDA-approved for obstructive sleep apnea | Zepbound |
Verdict
If you're optimizing for the highest expected weight loss and you can access Zepbound through insurance or LillyDirect at a price you can sustain, Zepbound is the trial-data winner. If you want the cheaper cash-pay path, the longer real-world safety record, or the better odds on Medicare coverage, Wegovy is still the right call. Both are excellent drugs by the standards of pre-2021 weight loss medication.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate. The 2024 SURMOUNT-5 trial directly compared tirzepatide to semaglutide and found tirzepatide produced greater weight loss across all dose comparisons, validating the cross-trial signal.
| Wegovy | Zepbound | |
|---|---|---|
| Registration trial | STEP-1 (NEJM, 2021) | SURMOUNT-1 (NEJM, 2022) |
| Duration | 68 weeks | 72 weeks |
| Mean weight loss (max dose) | 14.9% | 20.9% |
| Effect vs placebo | 12.4 pp | 17.8 pp |
| Patients losing ≥5% | 86.4% | 91.0% |
| Patients losing ≥15% | 50.5% | 56.7% |
2026 cash-pay cost compared
Both manufacturers run direct-to-consumer cash channels (NovoCare for Wegovy, LillyDirect for Zepbound) which are dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.
| Channel | Wegovy | Zepbound |
|---|---|---|
| Retail cash | $1,349/mo | $1,099/mo |
| Manufacturer DTC | $199-$499/mo via NovoCare | $349-$549/mo via LillyDirect (vials cheaper than pens) |
| With insurance + PA | $25-$50/mo with prior authorization | $25-$50/mo with prior authorization |
| Compounded | $99-$249/mo via 503A pharmacies | $199-$349/mo via 503A pharmacies (regulatory exposure) |
When to choose Wegovy
Choose Wegovy if: (1) you're paying cash and starting out (NovoCare's $199 starter dose is hundreds cheaper than LillyDirect equivalents); (2) you're on Medicare Part D where Wegovy has broader formulary placement; (3) you want the drug with the longest real-world safety record at obesity-treatment doses; (4) your insurance has Wegovy on a lower formulary tier than Zepbound.
When to choose Zepbound
Choose Zepbound if: (1) you've tried semaglutide and didn't reach your goal weight (the dual-agonist mechanism produces greater average loss); (2) you have obstructive sleep apnea (the only GLP-1 with an FDA OSA indication as of 2024); (3) your insurance covers both equally; (4) you're cash-pay at the maintenance dose where LillyDirect's $549 is close enough to NovoCare's $499 that the efficacy difference is the deciding factor.
Programs that prescribe each
Top Wegovy programs
Top Zepbound programs
FAQ
Is Zepbound stronger than Wegovy?
Can you switch from Wegovy to Zepbound?
Are the side effects different?
Which is cheaper without insurance?
Are these covered by insurance?
Can a telehealth program prescribe both?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of 12 May 2026. Talk to a licensed clinician about which medication is appropriate for you.